Clinical Study Of Xuan Fei Zhu Yin Combined Intra Pleural Infusion Of Cisplatin For The Treatment Of Lung Cancer Malignant Pleural Effusion

Purpose:To evaluate the clinical efficacy of the administration of Xuan Fei Zhu Yin co mbined intra pleural infusion of cisplatin in lung cancer patients with malignant pleural effusion (MPE).Method:A total of 60 patients with malignant pleural effusion of lung cancer were enr olled at Jiangsu Cancer Hospital from September 2011 to June 2014. Patients were rand omly divided into treatment group (Xuan Fei Zhu Yin plus intra pleural infusion of cis platin) and control group (single use of intra pleural infusion of cisplatin) 30 patients e ach. The clinical efficacy was examined through monitoring and evaluating the pleural e ffusion, quality of life, clinical symptoms and adverse reactions etc such aspects.Results:1. Patients in both groups showed significant improvement in pleural effusion (P<0.01). The treatment group improvement is better than the control group with no statistical significance (P>0.05).2. Significant statistic difference was observed between the two groups in the evaluation of clinical symptoms (P<0.05). For the treatment group, the Symptom Score is 3.01±3.121 before and after treatment, as for the control group,the Symptom Score is 0.12±3.23 before and after treatment.3. No statistical significance (P>0.05) was observed between the treatment group and the control group in short-term efficacy though the treatment showed better result than the control group (70% VS 60%).4. In the evaluation of the KPS Score, no significant difference was observed between the two groups before treatment, and statistical significance (P<0.05) was shown after treatment, i.e. The treatment group KPS Score is higher than that of the control group. The treatment group showed statistical difference in KPS Score before and after treatment (P<0.05), whereas the control group showed no statistical difference before and after treatment (P>0.05).5. The two groups EORTC QLQ-C30 comparison:the emotional function of the treatment group has improved, the entire health condition compared to that before treatment and that of the control group has a statistical significance (P<0.05); the patients pain, difficult breathing etc of the two groups has improved compared to that before treatment (P<0.05), moreover the symptoms of fatigue of the treatment group has improved after treatment (P<0.05); the treatment group’s nausea, vomiting, loss of appetite, diarrhea etc such GI tract adverse reactions occurrence rate have obviously reduced compared to the treatment group(P<0.05).6. The numbers of patients had level Ⅰ, Ⅱ, Ⅲ and Ⅳ hematological toxicity in the treatment group are 14,5,0,0 respectively, and 18,8,0,0 in the control group. The numbers of patients who had level Ⅰ, Ⅱ, Ⅲ and Ⅳ digestive system toxicity are 15,3,0, 0 respectively in the treatment group, and 18,7,0,0 in the control group. The treatment group showed statistically less reported cases in hematological toxicity and digestive system toxicity (P<0.05).Conclusion:1. The administration of Xuan Fei Zhu Yin with intra pleural infusion of cisplatin did not improve the short-term efficacy in the treatment of malignant pleural effusion of lung cancer.2. The administration of Xuan Fei Zhu Yin with intra pleural infusion of cisplatin can improve clinical symptoms.3. The administration of Xuan Fei Zhu Yin with intra pleural infusion of cisplatin can improve the patients quality of life4. The administration of Xuan Fei Zhu Yin with intra pleural infusion of cisplatin can reduce the occurrence of the adverse reactions.